151 results about "Tumor immunity" patented technology

The invention discloses a preparation method and application of a dual-targeting carrier-free delivery system for enhancing anti-tumor immunity of NKT cells, Lys-alpha-GalCer is used as a raw material, and two molecules of LGC are connected through a disulfide bond to synthesize an amphiphilic LGC-SS-LGC micromolecule prodrug; the LGC-SS-LGC micromolecule prodrug is prepared into vesicles internally loaded with an NKT cell antigen presenting molecule CD1d and externally modified with polysarcosine through electrostatic adsorption through a film dispersion-probe ultrasonic method, finally a CD1d / LGC-SS-LGC / PSar dual-targeting carrier-free delivery system is formed, and the dual-targeting carrier-free delivery system can be used for liver cancer treatment after intravenous administration. In addition, the compound can be used for preparing a preparation for enhancing NKT cell Th1 type immune response. The dual-targeting carrier-free delivery system prepared by the invention can directly or indirectly enhance the anti-tumor immune effect of the NKT cells, and has a dual-synergistic effect.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in tumor immunity and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture antibody is prepared by coupling a biotinylated antibody with a fluorescent microsphere coated with biotin to obtain a capture antibody coupled with a fluorescent encoding microsphere, and the detection antibody is prepared by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody to obtain a fluorescent labeled antibody; the mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect various cell factors, the sample dosage is only 25 microliters, the kit is suitable for immune monitoring of iron overload and other chronic inflammation models, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

The invention relates to the technical field of data management, and discloses a data management platform and management method for tumor immunoassay. The method comprises the following steps: performing standardized acquisition and preprocessing on multi-source tumor immune data to obtain a standardized data set; performing wavelet decomposition and dimension reduction processing on the standardized data set to obtain a dimension reduction feature set; performing cross-center data calibration on the dimension reduction feature set to obtain a calibrated merged data set; performing annotation expansion on the calibrated merged data set to obtain a complete annotation data set; and performing immune feature weight calculation and hierarchical data management according to the complete annotation data set, and generating a hierarchical tumor immune data management structure with differentiated storage priorities. The method is different from a traditional unified storage mode, the heterogeneity of the tumor immune microenvironment is considered, differentiated storage priorities are distributed according to the immune value of the sample, and the computing resource distribution and data access efficiency is optimized.

The invention discloses a marker for predicting the curative effect of tumor immunotherapy as well as application and a detection method of the marker, and belongs to the technical field of biomedicine. The marker is glycerophosphorylcholine (GPC) in peripheral blood, and under the condition that the GPC level of peripheral plasma is low, it is judged that ICIs immunotherapy is poor in curative effect response. Peripheral blood samples are simple and noninvasive to obtain, longitudinal curative effect monitoring can be realized, the method is independent of tissue biopsy and is not influenced by tumor heterogeneity, the cost is reduced, and application is facilitated; meanwhile, peripheral blood not only objectively reflects the systematic immune state of a host, but also is closely related to tumor immunity as an important ring in a tumor immune cycle, and in the aspect of accuracy, the efficiency of a prediction model constructed by GPC reaches 0.886 and is remarkably higher than that of PDL1.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The present invention discloses a metal complex tailed with an immunologically active molecule, as well as its preparation method and application. The metal complex tailed with an immunologically active molecule exhibits significant anticancer activity. On the one hand, the metal complex exerts cytotoxicity against rapidly growing cancer cells through its active ingredient with anti-tumor immune efficacy. On the other hand, it can also induce immunogenic cell death, enabling the host immune system to attack tumor cells and induce a tumor-specific immune response. (The metal complex of the present invention has been shown to effectively induce immunogenic cell death in non-small cell lung cancer cells and successfully activate anti-tumor immunity in mice in vaccine experiments.) Therefore, the metal complex of the present invention has outstanding effects in anti-cancer, anti-inflammatory, inducing immunogenic cell death, and achieving anti-tumor immunity, and has broad application prospects.

The application discloses a lanthanide rare earth nano probe and a preparation method and application thereof, the probe is RENPs, the RENPs take NaNdF4:Yb@NaLuF4 as an imaging element, and the plerixafor is a targeting element.The application provides a lanthanide rare earth nano probe and a preparation method and application thereof, takes NaNdF4:Yb@NaLuF4 as an imaging element, and the small-molecule drug plerixafor is a targeting element, both are combined radiotherapy sensitization elements, a rare earth nano probe RENPs with good biocompatibility and stable NIR-Ⅱ luminescence is constructed, the probe can visualize breast cancer before radiotherapy, so that precise radiotherapy target delineation can be carried out, the sensitivity of tumor cells to radiation is improved during radiotherapy, so that the sensitivity of radiotherapy is improved, the anti-tumor immunity of the body is activated, and the treatment of the anti-PD-L1 immune checkpoint inhibitor in combination can effectively improve the immunotherapy responsiveness, and the prognosis of metastatic and recurrent triple-negative breast cancer patients who lose the opportunity of surgery is improved.

The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (eg., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1α) pathways and non-HIF-1α pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.

Pharmaceutical compositions and therapeutic methods are provided comprising a single-domain antibody consisting of SEQ ID NO:1 and a pharmaceutically acceptable carrier. The antibody inhibits KRAS GTPase activity and inhibits phosphorylation of STAT3. In certain embodiments, inhibition of KRAS results in decreased phosphorylation of ERK1 / 2. The antibody reduces tumor cell surface PD-L1 expression and reduces VEGF production. The antibody crosses the blood-brain barrier following systemic administration and may exhibit sustained biological activity in vivo. Methods are provided for treating KRAS-mutant cancers, including pancreatic cancer and triple negative breast cancer, and for enhancing anti-tumor immunity through reduction of PD-L1 expression.

The invention discloses a multifunctional double-drug delivery system based on metal collaborative treatment and application of the multifunctional double-drug delivery system, and belongs to the technical field of biological medicine. The double-drug delivery system is double-drug delivery lipidosome and comprises metal ions, a lipidosome membrane and active ingredients, the metal ions are adsorbed on the surface of the lipidosome membrane, and the active ingredients are wrapped in the lipidosome membrane; the metal ions are divalent metal ions; the active component consists of an STING agonist and a traditional Chinese medicine active monomer component. According to the double-drug delivery system, the STING agonist and the traditional Chinese medicine anti-inflammatory components are co-loaded through lipidosome, and multi-dimensional remodeling of a tumor microenvironment is achieved through the double effects of exciting tumor immunity and inhibiting inflammatory reaction; and meanwhile, by introducing metal ions, the lysosome escape efficiency of a liposome drug delivery system is effectively enhanced, so that the intracellular delivery efficiency of the drug is improved.

An in vivo and in vitro editing preparation method for CAR-MΦ targeting tumor stem cells, and a use thereof. The invention provides a chimeric antigen receptor-macrophage (CAR-MΦ) and a nano-carrier based on self-assembled nano-micelles, which can be applied to immunotherapy of glioma. According to the present invention, (PA)2 peptide nano-micelles loaded with CD133-CAR plasmids are constructed, and a citraconic anhydride-modified dextran, which is a group targeting macrophage specific target CD206, is adopted for modification. The carrier is used to realize CAR editing of macrophage in vivo and in vitro, so as to facilitate the re-education of tumor-related macrophage from an M2 phenotype to an M1 phenotype. At the same time, the surface markers of tumor stem cells are targeted to accurately target the tumor stem cells, phagocytize tumor cells, activate tumor immunity, remodel the tumor inhibition microenvironment and specifically kill brain glioma stem cells, thereby efficiently treating brain glioma.

This invention relates to the fields of brachytherapy and radiosensitization, specifically providing a... 125 I-nano implantable particles, their preparation methods, and applications. 125 The 1-nanometer implanted particles have a core-shell structure, consisting of a particle core and particles adsorbed on the outer surface of the particle core. 125 I and the particles encapsulated in the nucleus and 125 The outer shell of the I-type photosensitizer is a covalent organic framework. This invention... 125 The core of the I-nanometer implanted particle is used to enhance the energy deposition of gamma rays and X-rays, generating more hydroxyl radicals; the shell containing a type I photosensitizer is used to absorb the energy of Auger electrons and internal conversion electrons and excite the photosensitizer to generate singlet oxygen, effectively improving the response to... 125 The efficiency of I decay energy utilization. 125 I-nano implanted particles, combined with internal radiation therapy and radiodynamic therapy, destroy tumor cell DNA and cell membranes, enhance tumor killing and induce immunogenic cell death, thereby activating anti-tumor immunity and inducing remote effects.

Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same. Also described herein are methods of stimulating a cell-mediated immune response to a tumor, reducing tumor volume, or providing an anti-tumor immunity in a human subject in need thereof, the methods comprise administering to a subject multiple administrations of an immunoresponsive cell encoding a controlled release cytokine.

The invention belongs to the technical field of tumor immunity, and particularly relates to a tumor antigen and chemotactic factor co-coding system and application thereof. The invention provides a tumor antigen and chemotactic factor co-coding system. The tumor antigen and chemotactic factor co-coding system comprises a nucleotide sequence for coding a tumor antigen and a nucleotide sequence for coding a chemotactic factor. The tumor antigen and chemotactic factor co-coding system can flexibly replace an antigen sequence and chemotactic factor combination, is adaptive to different tumor types and various immunotherapy requirements, can be expanded to various solid tumor treatment scenes through a customized antigen-chemotactic factor combination in the future, and has a wide application prospect. The broad-spectrum application in tumor treatment means including tumor neoantigen vaccines, adoptive cell therapy and the like is realized.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

The invention relates to a cell membrane bionic drug-loaded carbon dot nano-material as well as a preparation method and application thereof. The nano-composite is prepared by the following steps: preparing carbon dots, cross-linking to form a reduction responsive carbon dot nano-cluster, sequentially loading chemotherapeutic drugs and coating a cancer cell membrane to form a nano-vaccine. After the nano vaccine is injected into the body of a mouse through caudal vein, the enrichment of the nano vaccine in a tumor part can be enhanced by utilizing the active tumor targeting characteristic of a cancer cell membrane, and tumor cells can be induced to generate immunogenic death through carried chemotherapy drugs and photothermal therapy, so that chemotherapy / photothermal / immune combined therapy on tumors is realized; the obvious anti-tumor effect is realized. In addition, as a nano vaccine, after subcutaneous injection, the nano vaccine can also utilize the tumor antigen carried by a cancer cell membrane and the adjuvant characteristics of the carbon dots to activate the anti-tumor immunity of an organism so as to prevent tumors, and has potential clinical application value.

The invention belongs to the technical field of medicines, and generally relates to application of N-acetyl-L-tyrosine and an N-acetyltransferase strain for expressing tyrosine in preparation of tumor treatment drugs or anti-tumor immune activation drugs for elderly individuals. Researches find that N-acetyl-L-tyrosine and a tyrosine-expressing N-acetyltransferase strain can significantly inhibit mouse tumors, which shows that the mouse tumors grow slowly or the number of the mouse tumors is reduced. The N-acetyl-L-tyrosine can also regulate anti-tumor immunity, and is expressed as promoting TCF1 expression and increasing the proportion of depleted precursor T cells. In the elderly, the curative effect is particularly prominent. The results show that N-acetyl-L-tyrosine and related strains thereof can be used for tumor treatment and anti-tumor immune aging regulation.

This invention discloses a cell preparation targeting bone metastatic tumor cells, its preparation method, and its application, belonging to the field of biomedical technology. The cell preparation comprises senescent neutrophils and drug-loaded cationic liposomes internalized within them. The cationic liposomes encapsulate a STING agonist and a pan-photokinase inhibitor. The preparation method includes: preparing drug-loaded liposomes using a thin-film dispersion-ultrasound method; obtaining senescent neutrophils through in vitro culture of extracted neutrophils; and preparing a senescent neutrophil preparation loaded with liposomes. This invention utilizes the natural bone marrow homing ability of senescent neutrophils to achieve precise targeting of bone metastatic tumor cells, and co-delivers two drugs through liposomes, simultaneously activating anti-tumor immunity and inducing tumor cell apoptosis / autophagy, synergistically treating bone metastases. This system has high drug loading capacity, good encapsulation efficiency, and sustained-release effect, and the preparation process is simple and controllable, providing a new strategy for the treatment of cancer bone metastases.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The invention relates to application of an EEPD1 inhibitor in improvement of colorectal cancer immunotherapy sensitivity. The invention determines that the expression of EEPD1 in advanced colorectal cancer is increased, and the EEPD1 is closely related to immune tolerance and poor prognosis of colorectal cancer; proliferation and metastasis of colorectal cancer cells can be inhibited in vivo and in vitro through targeting EEPD1, the microenvironment of colorectal cancer immune tolerance is improved, more immune cells are activated to participate in anti-tumor immunity, and then the immunotherapy curative effect of the PD-1 antibody is improved. According to the invention, the understanding of the prior art on the PD-1 treatment drug resistance potential mechanism of the colorectal cancer patient is deepened, a theoretical basis is provided for optimizing the colorectal cancer immunotherapy strategy, and a new direction is provided for potential treatment target mining and drug research and development of the colorectal cancer.

This invention discloses a method for inducing B-CD4 + Freeze-dried tumor tissue with T-cell interaction, its preparation method, and its applications. This study aims to address the lack of effective treatments for postoperative recurrence of microsatellite stable (MSS) solid tumors, the easy degradation and inactivation of traditional autologous whole antigen vaccines, insufficient presentation efficiency, and the limitation of only activating classical CD8. + The core bottleneck of the T cell pathway. This invention utilizes vacuum freeze-drying technology to prepare porous, degradable freeze-dried tumor tissue (LT) from clinically derived or artificially cultured tumor tissue. This process fully preserves the tumor's complete antigen spectrum, tumor-specific antigens, and the immunogenicity of related antigens. It allows for highly efficient antigen presentation via dendritic cells, specifically inducing B cells and CD4+. + T-cell interaction mediates non-classical anti-tumor immunity that does not rely on traditional cytotoxic immune cells, significantly inhibiting the growth of residual lesions after solid tumor surgery. It has both broad-spectrum anti-cancer effects and excellent biosafety, and is especially suitable for postoperative adjuvant immunotherapy for MSS-type colorectal cancer.

Disclosed are compositions and methods for targeted treatment of SSTR-expressing cancers. For example, disclosed herein are Bispecific T-Cell Engaging (BiTE) molecules (fusion polypeptides) (also referred to herein as bispecific molecules) that are able to crosslink CD3 complex on immune effector cells with SSTR2 on NETs. Also disclosed are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill SSTR-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a SSTR-expressing cancer, such as a neuroendocrine tumor, that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

The invention discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors, belongs to the technical field of anti-tumor traditional Chinese medicines, and discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-25 parts of ginseng, 15-18 parts of selfheal, 12-18 parts of seaweed, 12-19 parts of astragalus membranaceus, 10-16 parts of angelica sinensis, 18-30 parts of oldenlandia diffusa, 10-15 parts of fleece-flower root, 10-14 parts of poria cocos, 10-16 parts of thunberg fritillary bulb, 8-14 parts of pseudobulbus cremastrae seu pleiones and 8-17 parts of curcuma zedoary. Through the specific pharmacological action, growth and proliferation of thyroid tumor cells are inhibited, the development speed of tumors can be slowed down, the malignancy degree of the tumors can be reduced, apoptosis of the thyroid tumor cells can be induced, and the number of the tumor cells can be effectively reduced by inducing apoptosis of the tumor cells, so that the anti-tumor purpose is achieved.

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

Disclosed are means, methods, and compositions of matter useful for treatment of oncological indications through stimulation of protective anti-cancer immunity. In one embodiment the invention discloses the unexpected effect of astrocytes to augment immune stimulating activities of dendritic cells. In one embodiment dendritic cells are pulsed with tumor lysates and subsequently co-cultured with astrocytes in the presence of toll-like receptor agonists.

The invention belongs to the technical field of tumor vaccine development, and particularly relates to a tumor cell vaccine of gene knockout MSH2 as well as a preparation method and application of the tumor cell vaccine. Aiming at the problems that the immunogenicity of pMMR tumor cells is low and the tumor cell vaccine prepared from the pMMR tumor cells is difficult to activate an organism to generate effective anti-tumor immunity, the invention provides a cell vaccine of gene knockout MSH2 as well as a preparation method and application of the cell vaccine. The invention discovers that the immunotherapy effect of the tumor cell vaccine can be improved by knocking out the MSH2 for the first time, and proves that the MSH2 can be used as a new transformation target of the tumor cell vaccine. The vaccine is prepared from MSH2 gene knockout tumor cells through irradiation inactivation, it is found that the vaccine can remarkably inhibit growth of far-end subcutaneous tumors and AOM + DSS induced primary colorectal cancer tumors, meanwhile, long-term broad-spectrum anti-tumor immune memory can be induced, and growth of heterogeneous tumor cells is effectively inhibited. In conclusion, the invention has potential significance in clinical application of broad-spectrum tumor cell vaccines.

The application relates to the technical field of tumor drugs, in particular to application of METTL5 as a tumor immunotherapy targeting site. The base sequence of the METTL5 is shown in SEQ ID No. 1; wherein the METTL5 is a brand-new RNAm6A methyltransferase, is closely related to ribosome translation function, and can regulate the translation of a tumor immune key regulator IL-27; therefore, the METTL5 is used as the tumor immunotherapy targeting site, the expression of the METTL5 related genes or coding proteins is inhibited through targeting, the body anti-tumor immunity can be effectively stimulated, the METTL5 becomes the targeting site capable of enhancing the response rate of tumor immunotherapy, and the METTL5 used as the tumor treatment target point has a wide application prospect in the anti-tumor immunotherapy.

The invention discloses application of a VCP inhibitor combined with an STING agonist in preparation of a medicine for treating colorectal cancer, and belongs to the technical field of biological medicines. The regulation and control effect of the VCP on a cGAS-STING signal channel is proved, and the anti-tumor immunity driven by the cGAS-STING can be enhanced by pharmacological inhibition of the VCP, so that the VCP inhibitor is put forward to be applied to anti-tumor treatment as an STING agonist anti-tumor sensitizer. The VCP inhibitor can enhance the treatment effect of the STING agonist on the colorectal cancer through the drug synergistic effect, and the combined treatment tolerance is good. The invention provides the application of the VCP inhibitor and the STING agonist in preparing the medicine for treating the colorectal cancer, provides a new way for clinical transformation for treating the colorectal cancer, and has an application value.

The invention discloses a copper-manganese alloy drug loading system and a preparation method and application thereof.The preparation method of the copper-manganese alloy drug loading system at least comprises the following steps that S1, gas-atomized copper-manganese powder serves as a raw material, the 3D printing technology is used for printing the gas-atomized copper-manganese powder, and a copper-manganese alloy precursor is obtained; s2, the copper-manganese alloy precursor is placed in a dealloying solution for dealloying, and the copper-manganese alloy of the porous nanostructure is obtained; and S3, loading an anti-tumor drug on the copper-manganese alloy with the porous nanostructure to obtain the copper-manganese alloy drug loading system. The copper-manganese alloy drug delivery system selectively releases manganese ions, can widely inhibit expression of cancer cell glycolysis related genes, hinder cancer cell glycolysis, mediate cancer cell pyroptosis and activate anti-tumor immunity, KHK-IN-2 can inhibit cancer-promoting macrophage fructose metabolism, finally macrophage metabolism-immune reprogramming is achieved, and the anti-tumor curative effect is further enhanced.